Dr. Vincent A. Miller describes study results that suggest the addition of erlotinib to bevacizumab treatment for advanced non-small cell lung cancer extends progression-free survival compared with bevacizumab alone. Damian McNamara of the Global Medical News Network (GMNN) reports from the annual meeting of the American Society of Clinical Oncology in Orlando.